X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (96480) 96480
Publication (5372) 5372
Newsletter (5295) 5295
Book Review (552) 552
Newspaper Article (431) 431
Book Chapter (311) 311
Magazine Article (244) 244
Dissertation (125) 125
Conference Proceeding (107) 107
Book / eBook (34) 34
Trade Publication Article (27) 27
Web Resource (16) 16
Reference (8) 8
Transcript (8) 8
Data Set (5) 5
Journal / eJournal (3) 3
Presentation (2) 2
Streaming Video (2) 2
Government Document (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (75772) 75772
female (47036) 47036
male (42827) 42827
middle aged (41212) 41212
index medicus (38142) 38142
aged (35680) 35680
squamous cell carcinoma (32708) 32708
oncology (31972) 31972
cancer (30575) 30575
adult (28534) 28534
carcinoma, squamous cell - pathology (25288) 25288
squamous-cell carcinoma (23521) 23521
prognosis (18164) 18164
surgery (16544) 16544
radiotherapy (14872) 14872
carcinoma, squamous cell - radiotherapy (14247) 14247
carcinoma, squamous cell - drug therapy (14135) 14135
aged, 80 and over (13867) 13867
carcinoma, squamous cell - surgery (13495) 13495
neoplasm staging (13315) 13315
chemotherapy (12944) 12944
care and treatment (12392) 12392
carcinoma, squamous cell - therapy (12371) 12371
retrospective studies (11890) 11890
research (11882) 11882
treatment outcome (10716) 10716
carcinoma, squamous cell - mortality (9922) 9922
combined modality therapy (9541) 9541
tumors (9329) 9329
metastasis (9182) 9182
head (9149) 9149
analysis (8709) 8709
animals (8499) 8499
follow-up studies (8394) 8394
survival (8236) 8236
otorhinolaryngology (8029) 8029
survival rate (7839) 7839
head and neck cancer (7775) 7775
carcinoma (7622) 7622
expression (7184) 7184
esophageal cancer (6997) 6997
carcinoma, squamous cell - metabolism (6784) 6784
health aspects (6643) 6643
antineoplastic combined chemotherapy protocols - therapeutic use (6465) 6465
lymphatic metastasis (6302) 6302
carcinoma, squamous cell - genetics (6229) 6229
immunohistochemistry (6194) 6194
head and neck neoplasms - pathology (6097) 6097
radiology, nuclear medicine & medical imaging (6025) 6025
risk factors (5992) 5992
cell line, tumor (5904) 5904
therapy (5653) 5653
radiation-therapy (5624) 5624
apoptosis (5603) 5603
medicine & public health (5275) 5275
mice (5228) 5228
survival analysis (5218) 5218
carcinoma, squamous cell - diagnosis (5182) 5182
radiotherapy dosage (4934) 4934
neck-cancer (4870) 4870
esophageal neoplasms - pathology (4856) 4856
disease-free survival (4802) 4802
patients (4787) 4787
head and neck neoplasms - drug therapy (4741) 4741
carcinoma, squamous cell - secondary (4722) 4722
pathology (4638) 4638
cisplatin (4627) 4627
hematology, oncology and palliative medicine (4478) 4478
genetic aspects (4463) 4463
adenocarcinoma - pathology (4435) 4435
diagnosis (4431) 4431
radiation therapy (4336) 4336
development and progression (4314) 4314
cisplatin - administration & dosage (4313) 4313
head and neck neoplasms - radiotherapy (4277) 4277
antineoplastic agents - therapeutic use (4260) 4260
gene expression (4230) 4230
radiation (4180) 4180
chemoradiotherapy (4148) 4148
medical prognosis (4120) 4120
time factors (4113) 4113
cancer therapies (4096) 4096
oncology, experimental (4054) 4054
adenocarcinoma (3995) 3995
neck (3985) 3985
proteins (3830) 3830
dentistry, oral surgery & medicine (3792) 3792
lung cancer (3788) 3788
lung neoplasms - pathology (3768) 3768
mouth neoplasms - pathology (3683) 3683
cervical cancer (3610) 3610
uterine cervical neoplasms - pathology (3520) 3520
prospective studies (3473) 3473
head and neck neoplasms - therapy (3470) 3470
breast-cancer (3345) 3345
medicine (3261) 3261
neoplasm invasiveness (3259) 3259
dermatology (3211) 3211
medical research (3196) 3196
medicine, research & experimental (3181) 3181
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (95197) 95197
German (2427) 2427
Japanese (2322) 2322
French (1474) 1474
Chinese (901) 901
Russian (712) 712
Spanish (378) 378
Polish (359) 359
Italian (303) 303
Portuguese (85) 85
Korean (75) 75
Hungarian (67) 67
Dutch (58) 58
Czech (48) 48
Turkish (38) 38
Danish (29) 29
Serbian (24) 24
Bulgarian (22) 22
Norwegian (18) 18
Croatian (16) 16
Hebrew (16) 16
Romanian (16) 16
Finnish (11) 11
Ukrainian (11) 11
Lithuanian (7) 7
Swedish (6) 6
Arabic (5) 5
Slovak (5) 5
Icelandic (3) 3
Slovenian (3) 3
Greek (2) 2
Bosnian (1) 1
Georgian (1) 1
Indonesian (1) 1
Latvian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 08/2015, Volume 10, Issue 8, p. e0136023
Background Immunotherapy can become a crucial therapeutic option to improve prognosis for lung cancer patients. First clinical trials with therapies targeting... 
CELL LUNG-CANCER | TUMOR-INFILTRATING LYMPHOCYTES | INTERLEUKIN-2 | GEFITINIB | IMPACT | MULTIDISCIPLINARY SCIENCES | ANTIBODY | B7-H1 | T-CELLS | CHEMOTHERAPY | LIGAND 1 EXPRESSION | Adenocarcinoma - pathology | Prognosis | Follow-Up Studies | Lung Neoplasms - mortality | Carcinoma, Large Cell - pathology | Carcinoma, Squamous Cell - metabolism | Carcinoma, Squamous Cell - pathology | Humans | Lung Neoplasms - metabolism | Lung Neoplasms - pathology | Male | Carcinoma, Large Cell - mortality | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Carcinoma, Squamous Cell - mortality | Neoplasm Grading | Biomarkers, Tumor - metabolism | Female | Retrospective Studies | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - metabolism | Carcinoma, Squamous Cell - therapy | Programmed Cell Death 1 Receptor - metabolism | Survival Rate | Combined Modality Therapy | Lung Neoplasms - therapy | Carcinoma, Non-Small-Cell Lung - mortality | B7-H1 Antigen - metabolism | Carcinoma, Non-Small-Cell Lung - therapy | Adenocarcinoma - therapy | Aged | Neoplasm Staging | Carcinoma, Large Cell - therapy | Adenocarcinoma - mortality | Care and treatment | Physiological aspects | Genetic aspects | Research | Lung cancer, Non-small cell | Apoptosis | Immunohistochemistry | Thoracic surgery | PD-1 protein | Lung cancer | Clinical trials | Oncology | Cancer therapies | Lymph nodes | Subgroups | Proteins | Rank tests | Regression models | Bcl-x protein | Lymphocytes | Immunotherapy | Medical research | Immunoglobulins | Squamous cell carcinoma | Cell survival | Cytokines | Hematology | Tumor cells | Non-small cell lung carcinoma | Breast cancer | Regression analysis | Patients | Medicine | Pathology | Chemotherapy | Hospitals | Cell death | Medical prognosis | PD-L1 protein | Ligands | Diagnostic systems | Solid tumors | Cancer | Tumors | Lymph
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 187 - 199
Summary Background We aimed to compare overall survival after standard-dose versus high-dose conformal radiotherapy with concurrent chemotherapy and the... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | COMPETING RISK | CLINICAL-TRIALS | THERAPY ONCOLOGY GROUP | CHEMORADIATION | INDUCTION | CARCINOMA | CHEMOTHERAPY | RADIATION-THERAPY | Prognosis | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Carcinoma, Large Cell - mortality | Radiotherapy, Image-Guided | Chemoradiotherapy | Carcinoma, Large Cell - secondary | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Non-Small-Cell Lung - secondary | Carcinoma, Squamous Cell - mortality | Aged, 80 and over | Adult | Female | Cetuximab | Paclitaxel - administration & dosage | Radiotherapy Dosage | Carboplatin - administration & dosage | Carcinoma, Squamous Cell - therapy | Survival Rate | Combined Modality Therapy | Lung Neoplasms - therapy | Carcinoma, Non-Small-Cell Lung - mortality | Adenocarcinoma - secondary | Carcinoma, Non-Small-Cell Lung - therapy | Adenocarcinoma - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Radiotherapy, Conformal | Carcinoma, Squamous Cell - secondary | Aged | Neoplasm Staging | Carcinoma, Large Cell - therapy | Adenocarcinoma - mortality | Antimitotic agents | Care and treatment | Chemotherapy | Dosage and administration | Lung cancer, Non-small cell | Antineoplastic agents | Radiotherapy | Cancer | Index Medicus
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2012, Volume 84, Issue 1, pp. 189 - 195
Purpose To assess the outcomes, toxicity, and quality of life (QOL) of patients with primary parotid carcinoma treated with surgery and postoperative... 
Radiology | Hematology, Oncology and Palliative Medicine | Head-and-neck cancer | Parotid carcinoma | Radiotherapy | Toxicity | Quality of life | HEAD | PROGNOSTIC-FACTORS | ONCOLOGY | NECK | TUMORS | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | SALIVARY-GLAND CARCINOMA | Adenocarcinoma - pathology | Parotid Gland - surgery | Carcinoma, Acinar Cell - drug therapy | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Carcinoma, Acinar Cell - pathology | Carcinoma, Acinar Cell - radiotherapy | Carcinoma, Squamous Cell - surgery | Male | Carcinoma, Squamous Cell - radiotherapy | Young Adult | Carcinoma, Mucoepidermoid - radiotherapy | Netherlands | Carcinoma, Acinar Cell - secondary | Parotid Neoplasms - radiotherapy | Aged, 80 and over | Adult | Carcinoma, Adenoid Cystic - secondary | Female | Parotid Neoplasms - surgery | Carcinoma - pathology | Adenocarcinoma - radiotherapy | Carcinoma - secondary | Carcinoma, Adenoid Cystic - surgery | Carcinoma - drug therapy | Radiotherapy Dosage | Carcinoma, Mucoepidermoid - secondary | Carcinoma, Adenoid Cystic - pathology | Neoplasm Invasiveness | Treatment Outcome | Carcinoma, Mucoepidermoid - surgery | Carcinoma - radiotherapy | Cancer Care Facilities | Lymphatic Irradiation | Adenocarcinoma - secondary | Carcinoma, Mucoepidermoid - pathology | Disease-Free Survival | Regression Analysis | Adolescent | Parotid Neoplasms - pathology | Quality of Life | Carcinoma, Squamous Cell - secondary | Aged | Carcinoma, Adenoid Cystic - radiotherapy | Neoplasm Staging | Adenocarcinoma - surgery | Neck Dissection | Care and treatment | Carcinoma | Nuclear radiation | Patient outcomes | Surgery | Cancer | Index Medicus | Adenocarcinoma | Adenoid | Cell survival | Preservation | Risk groups | Radiation | Clinical trials | Adjuvants | Multivariate analysis | Survival | Risk factors | Side effects | Neck | Bell's palsy | squamous cell carcinoma | SURGERY | PATIENTS | FAILURES | METASTASES | TOXICITY | STANDARD OF LIVING | IRRADIATION | MULTIVARIATE ANALYSIS | HEALTH HAZARDS | CARCINOMAS | RADIOLOGY AND NUCLEAR MEDICINE | RADIOTHERAPY | SIDE EFFECTS
Journal Article
Cancer, ISSN 0008-543X, 07/2017, Volume 123, Issue 13, pp. 2404 - 2412
Cervical cancer is the fourth most common malignancy diagnosed in women worldwide. Nearly all cases of cervical cancer result from infection with the human... 
human papillomavirus (HPV) | developing world | Cervix Cancer Research Network (CCRN) | Gynecological Cancer InterGroup (GCIG) | brachytherapy | cervical cancer | chemotherapy | activism | vaccination | GYNECOLOGIC-ONCOLOGY-GROUP | FOLLOW-UP | RANDOMIZED-TRIAL | HUMAN-PAPILLOMAVIRUS | INTRAEPITHELIAL NEOPLASIA | RADIATION-THERAPY | UTERINE CERVIX | 9-VALENT HPV VACCINE | ONCOLOGY | DOSE-RATE BRACHYTHERAPY | LOCALLY ADVANCED-CARCINOMA | Carcinoma, Squamous Cell - pathology | Carcinoma, Squamous Cell - virology | Humans | Carcinoma, Neuroendocrine - therapy | Uterine Cervical Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Chemoradiotherapy, Adjuvant | Fertility Preservation | Early Medical Intervention | Female | Brachytherapy | Radiotherapy, Adjuvant | Uterine Cervical Neoplasms - therapy | Carcinoma, Adenosquamous - pathology | Neoplasms, Cystic, Mucinous, and Serous - pathology | Papillomavirus Vaccines - therapeutic use | Global Health | Early Detection of Cancer | Uterine Cervical Neoplasms - prevention & control | Carcinoma, Squamous Cell - therapy | Carcinoma, Squamous Cell - prevention & control | Hysterectomy | Carcinoma, Small Cell - therapy | Neoplasms, Cystic, Mucinous, and Serous - therapy | Carcinoma, Adenosquamous - therapy | Cisplatin - therapeutic use | Carcinoma, Neuroendocrine - pathology | Papillomavirus Infections - prevention & control | Adenocarcinoma, Clear Cell - therapy | Uterine Cervical Neoplasms - virology | Adenocarcinoma, Clear Cell - pathology | Carcinoma, Small Cell - pathology | Prevention | Women | Usage | Chemotherapy | Radioisotope brachytherapy | Diagnosis | Radiotherapy | Health aspects | Cervical cancer | Cancer | Vaccination | Infections | Malignancy | Biology | Radiation therapy | Cervix | Cancer therapies | Cisplatin | Developing countries--LDCs | Human papillomavirus | Surgery | Public health
Journal Article
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, ISSN 0190-9622, 08/2011, Volume 65, Issue 2, pp. 253 - 261
Skin cancer is the most frequent malignancy in organ transplant recipients, 95% of which are nonmelanoma skin cancer, especially squamous cell and basal cell... 
HUMAN-PAPILLOMAVIRUS TYPES | voriconazole | RISK-FACTORS | LIVER-TRANSPLANTATION | immunosuppression | organ transplant recipients | RENAL-TRANSPLANTATION | MALIGNANT-MELANOMA | DERMATOLOGY | IMMUNOSUPPRESSIVE THERAPY | REDUCED INCIDENCE | KIDNEY-TRANSPLANTATION | sirolimus | nonmelanoma skin cancer | SQUAMOUS-CELL CARCINOMA | VORICONAZOLE THERAPY | Melanoma - epidemiology | Education, Medical, Continuing | Melanoma - etiology | Prognosis | Skin Neoplasms - drug therapy | Carcinoma, Squamous Cell - pathology | Humans | Male | Carcinoma, Basal Cell - epidemiology | Carcinoma, Merkel Cell - etiology | Carcinoma, Merkel Cell - drug therapy | Incidence | Sarcoma, Kaposi - drug therapy | Carcinoma, Basal Cell - etiology | Voriconazole | Female | Carcinoma, Merkel Cell - epidemiology | Sarcoma, Kaposi - epidemiology | Triazoles - therapeutic use | Skin Neoplasms - pathology | Sirolimus - therapeutic use | Risk Assessment | Carcinoma, Squamous Cell - epidemiology | Sarcoma, Kaposi - etiology | Treatment Outcome | Carcinoma, Basal Cell - pathology | Melanoma - pathology | Skin Neoplasms - epidemiology | Sarcoma, Kaposi - pathology | Carcinoma, Squamous Cell - etiology | Carcinoma, Squamous Cell - drug therapy | Pyrimidines - therapeutic use | Organ Transplantation - adverse effects | Survival Analysis | Carcinoma, Basal Cell - drug therapy | Organ Transplantation - methods | Skin Neoplasms - etiology | Immunocompromised Host | Carcinoma, Merkel Cell - pathology
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 07/2017, Volume 77, Issue 13, pp. 3540 - 3550
Antibody targeting of the immune checkpoint receptor PD1 produces therapeutic activity in a variety of solid tumors, but most patients exhibit partial or... 
BREAST-CANCER | BIOMARKERS | ANTI-PD-1 THERAPY | PEMBROLIZUMAB | ONCOLOGY | CLINICAL ONCOLOGY/COLLEGE | RECOMMENDATIONS | SENSITIVITY | MECHANISMS | TUMORS | AMERICAN SOCIETY | Gene Expression - drug effects | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Squamous Cell Carcinoma of Head and Neck | Melanoma - genetics | Gene Expression - immunology | Aged, 80 and over | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma, Non-Small-Cell Lung - genetics | Head and Neck Neoplasms - drug therapy | Gene Expression Profiling - methods | Melanoma - pathology | Head and Neck Neoplasms - pathology | Carcinoma, Non-Small-Cell Lung - immunology | Lung Neoplasms - immunology | Carcinoma, Squamous Cell - drug therapy | Melanoma - immunology | Melanoma - drug therapy | Nivolumab | Head and Neck Neoplasms - genetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Programmed Cell Death 1 Receptor - genetics | PD-1 protein | CD8 antigen | Antibodies | Activation | Lymphocytes T | Killer cells | Cell activation | Lymphocytes | Natural killer cells | Signatures | Immune system | Squamous cell carcinoma | Head | Immune response | Small cell lung carcinoma | Tumor-infiltrating lymphocytes | Melanoma | Lung carcinoma | Gene expression | Ribonucleic acid--RNA | Patients | CD4 antigen | Immune checkpoint | Reproducibility | PD-L1 protein | Biomarkers | Head and neck cancer | Interferon | Solid tumors | Cancer | Tumors
Journal Article
American Journal of Surgical Pathology, ISSN 0147-5185, 03/2012, Volume 36, Issue 3, pp. 321 - 330
High-grade neuroendocrine carcinoma of the head and neck is an aggressive neoplasm which rarely arises in the oropharynx. Here we report a series of 8... 
neuroendocrine carcinoma | head and neck cancer | oropharynx | human papillomavirus | squamous cell carcinoma | SQUAMOUS-CELL-CARCINOMA | SURGERY | PATHOLOGY | HUMAN-PAPILLOMAVIRUS DNA | NECK-CANCER | ADENOSQUAMOUS CARCINOMA | SITU HYBRIDIZATION | UTERINE CERVIX | RISK-FACTOR | IMMUNOHISTOCHEMICAL ANALYSIS | UNDIFFERENTIATED CARCINOMA | TRANSCRIPTION FACTOR-I | Immunohistochemistry | Oropharyngeal Neoplasms - therapy | Smoking - adverse effects | Carcinoma, Small Cell - secondary | Carcinoma, Neuroendocrine - etiology | Carcinoma, Squamous Cell - virology | Humans | Middle Aged | Carcinoma, Neuroendocrine - therapy | Carcinoma, Small Cell - virology | DNA, Viral - analysis | Male | Oropharyngeal Neoplasms - pathology | Papillomaviridae - genetics | Papillomavirus Infections - therapy | Carcinoma, Small Cell - chemistry | In Situ Hybridization | Time Factors | Carcinoma, Small Cell - etiology | Polymerase Chain Reaction | Aged, 80 and over | Adult | Female | Papillomavirus Infections - virology | Carcinoma, Neuroendocrine - chemistry | Cell Differentiation | Human papillomavirus 18 - genetics | Papillomavirus Infections - complications | Risk Assessment | Biomarkers, Tumor - analysis | Risk Factors | Neoplasm Recurrence, Local | Carcinoma, Squamous Cell - therapy | Carcinoma, Squamous Cell - chemistry | Treatment Outcome | Carcinoma, Neuroendocrine - secondary | Lymphatic Metastasis | Oropharyngeal Neoplasms - virology | Mitotic Index | Carcinoma, Small Cell - therapy | Carcinoma, Squamous Cell - etiology | Oropharyngeal Neoplasms - etiology | Carcinoma, Squamous Cell - secondary | Oropharyngeal Neoplasms - chemistry | Aged | Carcinoma, Neuroendocrine - virology | Human papillomavirus 16 - genetics
Journal Article